Trazodone inhibits T-type calcium channels

Area of Science:

• Neuropharmacology
• Molecular Pharmacology

Background:

• Trazodone is widely prescribed for depression and insomnia, but its precise mechanism of action remains incompletely understood.
• While known to interact with serotonin and histamine receptors, its clinical efficacy at higher doses suggests additional targets.
• The contribution of other molecular targets to trazodone's pharmacological profile is an area of active investigation.

Purpose of the Study:

• To investigate the potential inhibitory effects of trazodone on T-type calcium channels.
• To determine if these effects occur at therapeutically relevant concentrations.
• To explore the contribution of T-type calcium channel inhibition to trazodone's neurological actions.

Main Methods:

• Whole-cell patch-clamp electrophysiology was used to study recombinant T-type calcium channels (Ca(v)3.1, Ca(v)3.2, Ca(v)3.3).
• The effects of trazodone and its metabolite, m-chlorophenylpiperazine, were assessed at various concentrations.
• Native T-type calcium currents were recorded from rat subthalamic neurons in brain slices.

Main Results:

• Trazodone demonstrated significant inhibition of all three recombinant T-type calcium channel subtypes (Ca(v)3.1, Ca(v)3.2, Ca(v)3.3) at therapeutically relevant concentrations.
• The metabolite m-chlorophenylpiperazine also inhibited T-type calcium channels, particularly Ca(v)3.3.
• Trazodone inhibited native T-type calcium currents in subthalamic neurons.

Conclusions:

• T-type calcium channel antagonism represents a novel pharmacological action of trazodone.
• This inhibition may contribute to the antidepressant and neurological effects associated with trazodone therapy.
• Further research is warranted to fully elucidate the clinical implications of T-type calcium channel blockade by trazodone.